Related Experiment Video
Updated: Apr 5, 2026

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
The long non-coding RNA KDM4A-AS1 protects β-cell function via the miR-423-5p/growth differentiation factor 11 axis
Background:
Type 2 diabetes mellitus (T2DM) is the most common type of diabetes, which can cause various complications that threaten health. Long non-coding RNA (lncRNA) is associated with the occurrence and development of diabetes and its complications.
Aim:
The aim is to explore the regulatory mechanism of lncRNA KDM4A-AS1 on T2DM and on the function of pancreatic β cells.
Methods:
We enrolled 98 T2DM patients and 91 healthy controls, measuring serum and cellular factor expression via RT-qPCR. Proliferation was assessed with CCK-8, apoptosis by flow cytometry and insulin secretion by ELISA. We confirmed KDM4A-AS1/miR-423-5p and miR-423-5p/ growth differentiation factor 11(GDF11) interactions using RNA immunoprecipitation and dual-luciferase reporter assays.
Results:
In the serum of patients with T2DM, the expressions of KDM4A-AS1 and GDF11 were significantly downregulated, while the expression of miR-423-5p was significantly upregulated. The level of KDM4A-AS1 was negatively correlated with fasting plasma glucose (FPG) and glycosylated haemoglobin (HbAlc). KDM4A-AS1 has a good diagnostic value for T2DM. Experiments conducted in vitro demonstrated that overexpression of KDM4A-AS1 could promote the expression of insulin synthesis genes Ins1 and Ins2, increase the amount of insulin secretion stimulated by glucose and simultaneously increase the cell proliferation rate and reduce the apoptosis rate. Mechanism studies have confirmed that KDM4A-AS1 can directly target miR-423-5p and exert protective effects on pancreatic β cells by regulating the expression of downstream GDF11.
Conclusions:
This study reveals that KDM4A-AS1 protects β-cell function through the miR-423-5p/GDF11 axis, providing a new potential target for the diagnosis and treatment of T2DM.
Insights
Long non-coding RNA KDM4A-AS1 protects pancreatic beta cells in type 2 diabetes by regulating the miR-423-5p/GDF11 pathway. This finding offers a novel diagnostic and therapeutic target for type 2 diabetes mellitus (T2DM).
Area of Science:
- Molecular Biology
- Endocrinology
- Genetics
Background:
- Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder with severe health complications.
- Long non-coding RNAs (lncRNAs) play a role in the pathogenesis of diabetes and its associated conditions.
Purpose of the Study:
- To investigate the regulatory mechanism of lncRNA KDM4A-AS1 in T2DM.
- To elucidate the role of KDM4A-AS1 in pancreatic beta cell function.
Main Methods:
- Serum samples from 98 T2DM patients and 91 healthy controls were analyzed for gene expression using RT-qPCR.
- In vitro studies assessed cell proliferation (CCK-8), apoptosis (flow cytometry), and insulin secretion (ELISA).
- RNA immunoprecipitation and dual-luciferase reporter assays confirmed interactions between KDM4A-AS1, miR-423-5p, and GDF11.
Main Results:
- KDM4A-AS1 and GDF11 were downregulated, while miR-423-5p was upregulated in T2DM patients' serum.
- KDM4A-AS1 levels correlated negatively with fasting plasma glucose and HbA1c, indicating diagnostic potential for T2DM.
- Overexpression of KDM4A-AS1 promoted insulin gene expression, enhanced glucose-stimulated insulin secretion, increased beta cell proliferation, and reduced apoptosis.
Conclusions:
- KDM4A-AS1 protects pancreatic beta cell function via the miR-423-5p/GDF11 signaling axis.
- KDM4A-AS1 represents a promising new target for T2DM diagnosis and treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation

